Aug 16,2021

Stroke therapy platform BrainQ closes a $40M funding round

BrainQ, an Israeli stroke therapy technology company, closed a funding round worth $40 million. Hanaco Ventures led the raise in addition to Dexcel Pharma, Peregrine Ventures and the company’s existing investors. These funds bring BrainQ’s total amount raised to over $50 million, according to the announcement. Following its FDA Breakthrough Device Designation from February, BrainQ will use the funds to support a multicenter pivotal trial for its stroke therapeutic device as it works to commercialize its product.

FUNDING VENTURE ROUND
View Analyst & Ambassador Comments
Go to original news
Aug 25,2021

Better Therapeutics Secures a Loan Facility Up to $50 million from Hercules Capital

Better Therapeutics has secured a loan facility for up to $50 million from Hercules Capital. The company, a prescription digital therapeutics platform that provides cognitive behavioral therapy to address diabetes, hypertension and other cardiometabolic diseases, announced earlier this year it planned to go public by merging with a special purpose acquisition company.

FUNDING DEBT FINANCE
View Analyst & Ambassador Comments
Go to original news
Sep 01,2021

Blue Note Therapeutics Raises $5.2M in Additional Series A Funding

Blue Note Therapeutics raised an additional $5.2 million in Series A financing, bringing the company’s Series A financing to a total of $31 million. The financing was provided by Memorial Sloan Kettering Cancer Center (MSK) and Alumni Ventures who joined Series A lead investors JAZZ Venture Partners and Summer VC.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Sep 09,2021

Neuroglee Raises $10M to Develop Virtual Neurology Clinics with Mayo Clinic, Others

Neuroglee, a Boston, MA-based provider of personalized evidence-based digital therapeutics (DTx) and virtual care solutions, today announced it has raised $10M in Series A funding led by OpenSpace Ventures with participation by EDBI. Neuroglee Therapeutics discovers, develops and commercializes personalized evidence-based digital therapeutics (DTx) and virtual care solutions to treat and manage patients with neurodegenerative diseases. In conjunction with the news of the funding round, Neuroglee is announcing plans to move its headquarters to Boston in Q4, as well as a collaboration with Mayo Clinic to co-develop Neuroglee Connect™, a novel clinical care program that will be based on Mayo Clinic’s Healthy Action to Benefit Independence & Thinking® (HABIT).

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Mar 01,2021

Pear Therapeutics tags another $20M to December's Series D round

Prescription digital therapeutics company Pear Therapeutics announced this morning that it has added $20 million more to an $80 million Series D funding round announced back in December. The company did not name any participants of this second closing, but highlighted "a leading national Integrated Delivery Network" as the source of the $20 million and the digital therapeutics company's newest strategic investor.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Mar 01,2021

Blue Note Therapeutics Raises $26.25 Million in Series A Financing

Blue Note Therapeutics, Inc., today announced the closing of a Series A financing round of $26.25 million. Proceeds will allow the company to scale the organization and fund near-term clinical trials of its lead prescription digital therapeutic (PDT), which will potentially improve the treatment of cancer. The capital will also support the development of Blue Note’s pipeline assets. The Series A financing was led by JAZZ Venture Partners and joined by Summer VC.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Mar 19,2021

Digital therapeutics company Happify Health secures $73M

Happify Health, a startup building digital therapeutics for people with chronic diseases, raised $73 million in new funding. The investments were led by Deerfield Management Company and included participation from Omega Capital Partners, ION Crossover Partners and existing investors. The fresh capital is part of a new series D and other "related financing," the company said.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Mar 24,2021

AppliedVR Secures $29 Million in Series a Funding to Make Virtual Reality the Standard of Care for Chronic Pain

AppliedVR, a pioneer advancing the next generation of digital medicine, announced $29 million in series A funding, bringing its total funds raised to date to $35 million. The round, which includes key investors F-Prime Capital, JAZZ Venture Partners, Sway Ventures, GSR Ventures, Magnetic Ventures and Cedars-Sinai, will fuel the company’s growth as it pursues full FDA approval over the next year.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Apr 07,2021

Better Therapeutics to Become Publicly Traded Prescription Digital Therapeutics Company via Merger with Mountain Crest Acquisition Corp. II

Better Therapeutics, Inc. a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, will go public, raising up to $113 million to advance its robust pipeline of products to treat cardiometabolic diseases, conditions which cost the U.S. healthcare system almost $500 billion each year. Better Therapeutics has entered into a definitive merger agreement with Mountain Crest Acquisition Corp II (Nasdaq: MCAD; “Mountain Crest II”), a publicly traded special purpose acquisition corporation or SPAC. The transaction values Better Therapeutics at a pro forma fully diluted enterprise value of approximately $187 million with existing Better Therapeutics shareholders rolling over 100% of their equity into equity of the combined company. Upon completion of the transaction, which is anticipated in the summer 2021, the combined company will operate as Better Therapeutics and securities are expected to be listed on Nasdaq under the symbol “BTTX.”

FUNDING IPO
View Analyst & Ambassador Comments
Go to original news
Apr 19,2021

Renovia raises $17M to help tackle female pelvic floor disorders

Renovia, a digital therapeutics maker for female pelvic floor disorders, today shared the closing of its Series C-1 financing round worth $17 million. The round included previous backers including Perceptive Life Sciences, Longwood Fund, Ascension Ventures and OSF Ventures, in addition to new investor Parian Global Management.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING